The estimated Net Worth of David S. Ege is at least $302 Tisíc dollars as of 15 August 2024. Dr Ege owns over 2,969 units of Seres Therapeutics Inc stock worth over $82,638 and over the last 4 years he sold MCRB stock worth over $76,272. In addition, he makes $142,708 as Exec. VP & Chief Technology Officer at Seres Therapeutics Inc.
Dr has made over 6 trades of the Seres Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 2,969 units of MCRB stock worth $3,117 on 15 August 2024.
The largest trade he's ever made was exercising 11,875 units of Seres Therapeutics Inc stock on 14 February 2024 worth over $12,469. On average, Dr trades about 4,122 units every 66 days since 2020. As of 15 August 2024 he still owns at least 78,703 units of Seres Therapeutics Inc stock.
You can see the complete history of Dr Ege stock trades at the bottom of the page.
Dr. David S. Ege Ph.D. is the Exec. VP & Chief Technology Officer at Seres Therapeutics Inc.
As the Exec. VP & Chief Technology Officer of Seres Therapeutics Inc, the total compensation of Dr D at Seres Therapeutics Inc is $142,708. There are 5 executives at Seres Therapeutics Inc getting paid more, with Eric Shaff having the highest compensation of $2,032,550.
Dr D is 47, he's been the Exec. VP & Chief Technology Officer of Seres Therapeutics Inc since . There are 16 older and 4 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.
David's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.
Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par... a Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
Seres Therapeutics Inc executives and other stock owners filed with the SEC include: